Integra LifeSciences (NASDAQ:IART) Issues Q4 Earnings Guidance

Integra LifeSciences (NASDAQ:IARTGet Rating) issued an update on its fourth quarter earnings guidance on Wednesday morning. The company provided EPS guidance of $0.92-0.96 for the period, compared to the consensus EPS estimate of $0.90.

Integra LifeSciences Stock Up 0.2 %

Shares of IART traded up $0.13 during mid-day trading on Wednesday, reaching $56.78. The company had a trading volume of 299,253 shares, compared to its average volume of 420,572. The company has a market capitalization of $4.74 billion, a price-to-earnings ratio of 27.50, a price-to-earnings-growth ratio of 1.60 and a beta of 1.14. Integra LifeSciences has a 52 week low of $40.67 and a 52 week high of $68.29. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.91 and a current ratio of 3.93. The firm has a 50-day moving average price of $55.82 and a 200 day moving average price of $51.69.

Integra LifeSciences (NASDAQ:IARTGet Rating) last released its quarterly earnings data on Wednesday, October 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.14. The business had revenue of $385.19 million for the quarter, compared to analysts’ expectations of $377.79 million. Integra LifeSciences had a return on equity of 16.41% and a net margin of 11.05%. On average, sell-side analysts forecast that Integra LifeSciences will post 3.33 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. JMP Securities lowered their price objective on Integra LifeSciences from $85.00 to $75.00 and set a market outperform rating on the stock in a research report on Thursday, October 27th. Morgan Stanley upped their price objective on Integra LifeSciences from $50.00 to $59.00 and gave the company an equal weight rating in a research report on Friday, January 6th. Truist Financial increased their price target on Integra LifeSciences from $52.00 to $58.00 and gave the company a hold rating in a report on Tuesday, December 20th. StockNews.com started coverage on Integra LifeSciences in a report on Wednesday, October 12th. They set a buy rating on the stock. Finally, Jefferies Financial Group started coverage on Integra LifeSciences in a report on Tuesday, October 11th. They set a hold rating and a $48.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, Integra LifeSciences has an average rating of Hold and an average price target of $58.33.

Institutional Investors Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Covestor Ltd increased its stake in shares of Integra LifeSciences by 63.0% in the 1st quarter. Covestor Ltd now owns 1,558 shares of the life sciences company’s stock worth $100,000 after purchasing an additional 602 shares in the last quarter. Captrust Financial Advisors increased its stake in shares of Integra LifeSciences by 95.0% in the 1st quarter. Captrust Financial Advisors now owns 2,003 shares of the life sciences company’s stock worth $129,000 after purchasing an additional 976 shares in the last quarter. PDT Partners LLC purchased a new stake in shares of Integra LifeSciences in the 2nd quarter worth $206,000. XTX Topco Ltd purchased a new stake in shares of Integra LifeSciences in the 1st quarter worth $248,000. Finally, Point72 Hong Kong Ltd increased its stake in shares of Integra LifeSciences by 59.6% in the 1st quarter. Point72 Hong Kong Ltd now owns 3,858 shares of the life sciences company’s stock worth $248,000 after purchasing an additional 1,441 shares in the last quarter. 87.60% of the stock is currently owned by hedge funds and other institutional investors.

About Integra LifeSciences

(Get Rating)

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company’s neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care, such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment, and the precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices.

See Also

Earnings History and Estimates for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.